CANCER AND LEUKEMIA GROUP B

描述(改编自申请者的摘要)： 芝加哥在实验室和临床癌症方面都有重大承诺。 自1930年以来的研究。作为该研究的临床翻译的一部分， 芝加哥大学及其癌症研究中心加入了癌症 和B组白血病(CALGB)，并在随后强烈 从科学和临床上支持CALGB。无数的协议， 委员会和项目由芝加哥的教职员工领导。在过去五年中 多年来，芝加哥大学从184名患者增加了收入 分到294分，1996年27%的主要成员的 病人应得的是非裔美国人。这些成就是由 主要成员的纪律活动，并通过支持七个 伊利诺伊州北部、密歇根州和 印第安纳州。芝加哥正在增加三家新的附属公司 明年，并将继续积极参与培训和质量控制 它的所有附属机构。本应用程序的目标是：(1) 将患者收益增加到300-350名患者/年；(2)领导和 协助CALGB在疾病相关委员会中的科学活动 呼吸系统(Vokes和Oak博士)、前列腺(Vogelzang、Steinberg和 Vijaykumar)、乳房(Fleming医生)、白血病(Larson医生)和胃肠道疾病(Dr. MANI)；(3)领导、协助和参与CALGB 心理学/肿瘤学(Marcy List，博士)、药理学和实验 治疗学(Ratain博士)、移植(Williams博士)、遗传学(Dr. 艾滋病相关恶性肿瘤(利博维茨博士)、外科肿瘤学(利博维茨博士)。 (4)鼓励芝加哥大学的教职员工 担任未来议定书的礼宾主席；以及(5)积极协助和 参加CALGB审计委员会、少数群体问题委员会、肿瘤学委员会 护理、癌症控制和放射治疗。芝加哥大学 建议通过以下方法实现这些目标：(1) 在新活力的帮助下增加主要成员的应计费用 结直肠癌、乳房、外科、白血病和前列腺癌的医生以及 通过为第一、第二和第三阶段议定书产生新的想法；(2)保持 附属医院的高应计利润和增加的应计利润 增加新的合格附属公司；(3)保持强大的领导作用 Vogelzang博士、Vokes博士、Larson博士、SChilsky博士、Ratain博士、Williams博士、Olopade博士 Vardiman和Michelassi在CALGB内；(4)招募新的年轻人 CALGB领导角色的调查人员(Manni、Leibowitz博士和 多尔蒂)；尤其是那些具有特定实验室专业知识的人 与临床治疗或结果相关；和(5)提供 多个CALGB管理委员会的志愿者。伊利诺伊大学 芝加哥及其附属公司仍然坚定地致力于为 他们各自的社区，特别是为妇女和妇女的需求服务 少数族裔。

DESCRIPTION (adapted from the applicant's abstract): The University of Chicago has had a major commitment to both laboratory and clinical cancer research since 1930. As part of the clinical translation of that research, the University of Chicago and its Cancer Research Center joined the Cancer and Leukemia Group B (CALGB) in 1985, and has subsequently strongly supported the CALGB both scientifically and clinically. Numerous protocols, committees, and programs are lead by Chicago faculty. Over the past five years the University of Chicago has increased its accrual from 184 patient points to 294 patient points, and in 1996 27 percent of the main member's patient accrual was African American. These accomplishments occurred by disciplined activity at the main member and also by supporting seven dedicated affiliated institutions in northern Illinois, Michigan and Indiana. Chicago is in the process of adding three new affiliates in the next year and remains very involved with the training and quality control of all its affiliate institutions. The goals of this application are: (1) increase the patient accrual to 300-350 patients/year; (2) to lead and assist CALGB scientific activities in the disease-related committees of respiratory (Drs. Vokes and Olak), prostate (Drs. Vogelzang, Steinberg and Vijaykumar), breast (Dr. Fleming), leukemia (Dr. Larson) and GI (Dr. Mani); (3) to lead and assist and participate in the CALGB committees such as psycho/oncology (Marcy List, Ph.D.), pharmacology and experimental therapeutics (Dr. Ratain), transplantation (Dr. Williams), genetics (Dr. Olopade), AIDS related malignancies (Dr. Liebowitz), surgical oncology (Dr. Michelassi) and pathology (Dr. Vardiman); (4) to encourage Chicago faculty to be protocol chairs for future protocols; and (5) to actively assist and participate in the CALGB committees of audit, minority issues, oncology nursing, cancer control, and radiotherapy. The University of Chicago proposes to accomplish these goals by the following methods: (1) to increase accrual from the main member with the assistance of new energetic physicians in colorectal, breast, surgery, leukemia and prostate cancer and by generating new ideas for phase I, II and III protocols; (2) to maintain the high accrual from the affiliate hospitals and increasing accrual by adding new qualified affiliates; (3) to maintain the strong leadership roles of Drs. Vogelzang, Vokes, Larson, Schilsky, Ratain, Williams, Olopade, List, Vardiman and Michelassi within the CALGB; (4) to recruit new young investigators to CALGB leadership roles (Drs. Manni, Leibowitz and Daugherty); especially those with a specific laboratory expertise which can be correlated with clinical treatment or outcome; and (5) to provide volunteers for numerous CALGB administrative committees. The University of Chicago and its affiliates remain firmly committed to serving all members of their respective communities, especially serving the needs of women and minorities.